Pacific Biosciences of California, Inc. PACB R2K
Company Overview
Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solutions to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-read sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, the company provides Revio, Vega, and Sequel instruments which conduct, monitor, and analyze single-molecule biochemical reactions on SMRT cell microchips; short-read sequencing; and onso instrument. It serves academic and governmental research institutions, commercial testing and service laboratories, genome centers, public health labs, hospitals and clinical research institutes, contract research organizations, pharmaceutical companies, and agricultural companies. The company markets its products through a sales force and distribution partners in Australia, certain parts of Asia, Europe, the Middle East, Africa, Central America, and South America. It has a collaboration with DNAstack Inc. to provide federated dataset of HiFi whole genome sequencing data. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.
Why Investors Should Care
Revenue has grown at a 55.6% CAGR over the past five years.
Recent Developments
- Dec 2025 Revenue of $160.00M (+3.9% YoY); net profit $-546.38M.
- Trailing 12 Months Year-on-year growth — revenue +0.1%.
- 5-Year Trend Long-term compounding — revenue CAGR 55.6%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 55.64% |
| 1 Year: | 0.10% |
Stock Price Performance
| 1 Year: | +2.74% |
| 6 Months: | -22.68% |
| 3 Months: | +3.45% |
| 1 Month: | +11.11% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMABelow
- RSI (14)48.94 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 55.6% over 5 years.
CONS
- Trading 43.8% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | PACB Pacific Biosciences of California, Inc. R2K | 1.50 | -3.66 | $465.90M | 0.00% | -77.87% | - | 55.64% | - |
| 2 | LLY Eli Lilly and Company SPX | 1,152.54 | 41.02 | $1.03T | 0.61% | - | 107.46% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPX | 253.85 | 29.45 | $611.07B | 2.23% | 14.88% | 26.42% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPX | 244.78 | 119.40 | $432.48B | 3.04% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPX | 425.19 | 32.02 | $386.13B | 2.27% | 9.74% | 12.18% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPX | 120.78 | 34.02 | $298.31B | 2.86% | - | 18.94% | 5.64% | 10.01% |
| 7 | AZN AstraZeneca PLC NDX | 164.50 | 24.81 | $255.12B | 1.77% | 15.97% | 23.48% | 9.82% | 45.96% |
| 8 | TMO Thermo Fisher Scientific Inc. SPX | 534.07 | 29.33 | $198.47B | 0.40% | 8.14% | 13.52% | 8.81% | 12.95% |
| 9 | AMGN Amgen Inc. NDXSPX | 355.25 | 24.69 | $191.73B | 2.84% | 18.02% | 101.32% | 11.77% | 5.58% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Dec 2014 | Mar 2015 | Jun 2015 | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | 24.91M | 20.07M | 23.55M | - | 19.36M | 21.58M | 18.16M | - | 16.43M | 24.62M | 21.91M | - | 15.60M | 19.08M | 19.08M | 29.00M | 30.61M | 34.89M | 33.17M | 35.47M | 32.31M | 38.90M | 47.57M | 55.69M | 38.81M | 36.01M | 39.97M | 37.15M | 39.77M | 38.44M | 37.18M |
| Gross Profit | 4.44M | 5.93M | 14.51M | 6.55M | 26.47M | 9.50M | 10.64M | 12.64M | 11.37M | 8.94M | 8.00M | 8.23M | 9.49M | 7.30M | 8.86M | 3.19M | 5.75M | 5.12M | 9.61M | 6.91M | 12.93M | 7.49M | 6.61M | 7.06M | 12.98M | 13.75M | 15.36M | 14.15M | 16.19M | 13.55M | 9.76M | 15.55M | 17.90M | 11.28M | 5.94M | 10.00M | -1.37M | 14.68M | 15.90M | 12.84M |
| Operating Income | -17.89M | -19.33M | -11.36M | 2.61M | -1.06M | -18.57M | -18.07M | -16.73M | -17.87M | -23.30M | -24.39M | -21.57M | -20.53M | -23.95M | -21.75M | -24.67M | -30.62M | -30.13M | -24.38M | -28.11M | -17.92M | -32.71M | -23.52M | -24.18M | -33.71M | -37.57M | -74.48M | -77.52M | -67.97M | -74.62M | -91.25M | -73.17M | -82.49M | -81.36M | -175.85M | -64.08M | -428.93M | -44.85M | -38.88M | -8.36M |
| Net Income | -18.98M | -20.17M | -11.94M | 1.82M | -1.41M | -19.35M | -18.50M | -17.49M | -19.03M | -23.87M | -25.54M | -22.02M | -20.76M | -24.18M | -22.54M | -25.04M | -30.80M | -30.32M | -24.60M | -29.12M | -91.00K | 1.26M | -23.09M | -23.71M | -87.44M | -41.00M | 16.54M | -81.50M | -71.39M | -76.97M | -88.02M | -69.83M | -66.87M | -78.18M | -173.32M | -60.73M | -426.07M | -41.93M | -38.00M | -8.28M |
| Diluted EPS | - | - | - | 0.02 | - | - | - | -0.19 | - | - | - | - | - | - | - | - | - | -0.20 | - | - | - | 0.01 | -0.15 | -0.14 | -0.45 | -0.21 | 0.08 | -0.37 | -0.32 | -0.34 | -0.36 | -0.28 | -0.26 | -0.29 | -0.64 | -0.22 | -1.44 | -0.14 | -0.13 | -0.03 |
| R&D Expense | - | 14.48M | 15.04M | 16.16M | - | 16.36M | 17.52M | 17.48M | - | 16.97M | 16.88M | 15.84M | - | 16.31M | 15.66M | 14.36M | - | 15.48M | 14.91M | 14.96M | - | 15.25M | 15.01M | 16.47M | 20.55M | 22.27M | 27.51M | 52.94M | 50.35M | 47.09M | 48.94M | 46.17M | 47.51M | 43.45M | 38.48M | 25.52M | 29.05M | 22.53M | 22.85M | 19.61M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 135.00K | 1.67M | 33.86M | 25.98M | 28.18M | 60.59M | 92.78M | 90.71M | 93.47M | 78.63M | 90.89M | 78.89M | 130.51M | 128.30M | 200.52M | 154.01M | 160.00M |
| Gross Profit | 135.00K | 1.67M | 13.03M | 940.00K | 6.42M | 23.40M | 53.45M | 44.16M | 34.66M | 25.10M | 34.58M | 32.57M | 58.86M | 49.03M | 52.78M | 37.28M | 45.78M |
| Operating Income | - | - | -109.76M | -94.34M | -77.54M | -62.85M | -29.13M | -71.24M | -89.78M | -100.99M | -100.55M | -104.39M | -210.44M | -307.20M | -334.47M | -474.31M | -553.86M |
| Net Income | -87.70M | -140.17M | -109.39M | -94.47M | -79.29M | -66.16M | -31.70M | -74.38M | -92.19M | -102.56M | -84.13M | 29.40M | -181.22M | -314.25M | -306.74M | -309.85M | -546.38M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | -0.76 | -0.55 | 0.17 | -0.89 | -1.40 | -1.21 | -1.59 | -1.82 |
| R&D Expense | 75.88M | 111.82M | 76.08M | 47.62M | 45.22M | 48.23M | 60.44M | 67.62M | 65.32M | 62.59M | 59.63M | 64.15M | 112.90M | 193.00M | 187.17M | 134.92M | 97.31M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 305.75M | 218.32M | 129.68M | 136.19M | 124.39M | 131.11M | 137.88M | 144.08M | 170.28M | 147.99M | 413.98M | 2.01B | 1.77B | 1.75B | 1.26B | 784.08M |
| Total Equity | -93.39M | -177.12M | 279.87M | 191.46M | 109.38M | 69.18M | 54.95M | 73.54M | 84.67M | 86.10M | 114.06M | 54.92M | 335.49M | 790.99M | 562.90M | 701.30M | 506.59M | 5.35M |
| Cash & Equivalents | 78.46M | 89.23M | 147.65M | 58.87M | 46.54M | 26.36M | 36.45M | 33.63M | 16.77M | 16.51M | 18.84M | 29.63M | 81.61M | 460.73M | 325.09M | 179.91M | 55.37M | 63.71M |
| Long Term Debt | - | - | 2.93M | 2.79M | 2.61M | 13.35M | 14.12M | - | 16.11M | 13.63M | 14.66M | 15.87M | - | 896.07M | 896.68M | - | - | - |
| Total Liabilities | - | - | 25.88M | 26.85M | 20.30M | 67.00M | 69.44M | 57.57M | 53.22M | 57.98M | 56.21M | 93.07M | 78.49M | 1.22B | 1.20B | 1.04B | 753.85M | 778.73M |
| Current Liabilities | - | - | 20.84M | 19.38M | 14.74M | 22.55M | 31.49M | 38.18M | 33.77M | 28.64M | 26.88M | 49.15M | 38.50M | 71.71M | 263.33M | 95.03M | 66.30M | 72.83M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -74.84M | -122.00M | -102.97M | -76.82M | -29.83M | - | - | -67.93M | -67.52M | -66.43M | -78.31M | 19.50M | -111.18M | -263.21M | -259.17M | -206.06M | -111.21M |
| Investing Cash Flow | 18.59M | -138.25M | 6.45M | 61.79M | -33.12M | - | - | -14.86M | -1.55M | -38.41M | 62.05M | -219.32M | -678.53M | 116.08M | 4.60M | 124.00M | 115.45M |
| Financing Cash Flow | 67.01M | 318.66M | 7.74M | 2.71M | 42.77M | - | - | 65.93M | 68.81M | 107.18M | 26.55M | 251.84M | 1.17B | 9.62M | 108.89M | -42.99M | 3.43M |
| Capital Expenditure | -5.18M | -5.26M | -9.28M | -1.70M | -909.00K | -1.61M | -3.01M | -8.21M | -10.43M | -1.85M | -2.84M | -1.04M | -5.93M | -16.75M | -8.84M | -6.19M | -2.71M |
| Free Cash Flow | -80.02M | -127.25M | -112.26M | -78.53M | -30.74M | - | - | -76.14M | -77.95M | -68.28M | -81.15M | 18.46M | -117.11M | -279.96M | -268.02M | -212.25M | -113.92M |
| Share Buybacks | 8.00K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 100.0% | 100.0% | 38.5% | 3.6% | 22.8% | 38.6% | 57.6% | 48.7% | 37.1% | 31.9% | 38.0% | 41.3% | 45.1% | 38.2% | 26.3% | 24.2% | 28.6% |
| Operating Margin % | - | - | -324.1% | -363.1% | -275.2% | -103.7% | -31.4% | -78.5% | -96.1% | -128.4% | -110.6% | -132.3% | -161.2% | -239.4% | -166.8% | -308.0% | -346.2% |
| Net Margin % | -64,965.2% | -8,373.1% | -323.0% | -363.6% | -281.4% | -109.2% | -34.2% | -82.0% | -98.6% | -130.4% | -92.6% | 37.3% | -138.9% | -244.9% | -153.0% | -201.2% | -341.5% |
| ROE % | 49.5% | -50.1% | -57.1% | -86.4% | -114.6% | -120.4% | -43.1% | -87.8% | -107.1% | -89.9% | -153.2% | 8.8% | -22.9% | -55.8% | -43.7% | -61.2% | -10,214.5% |
| ROCE % | - | - | -55.2% | -82.1% | -68.2% | -67.7% | -31.4% | -68.4% | -77.8% | -70.4% | -101.7% | -27.8% | -10.9% | -20.4% | -20.3% | -39.7% | -77.9% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | ARK Investment Management, LLC | 11.68% | 36.27M | $61.85M |
| 2 | Blackrock Inc. | 8.13% | 25.27M | $43.08M |
| 3 | Softbank Group Corporation | 6.58% | 20.45M | $34.87M |
| 4 | Vanguard Capital Management LLC | 4.11% | 12.78M | $21.79M |
| 5 | Sumitomo Mitsui Trust Group, Inc. | 2.27% | 7.04M | $12.00M |
| 6 | Amova Asset Management Americas Inc | 2.27% | 7.04M | $12.00M |
| 7 | Geode Capital Management, LLC | 2.25% | 6.98M | $11.89M |
| 8 | State Street Corporation | 1.97% | 6.12M | $10.44M |
| 9 | Millennium Management Llc | 1.58% | 4.89M | $8.34M |
| 10 | Shaw D.E. & Co., Inc. | 1.17% | 3.64M | $6.20M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for PACB
Pacific Biosciences of California (PACB) Dips More Than Broader Market: What You Should Know - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMiqAFBVV95cUxQSy1OXzdXOEhDTmJCTV9YeG9MQXMyV2dYNTV3V2JFVFV0aWNhcl9zLTVZQmJwVl9uXzRrRWpqMTFtRGR2S2tNdkdDVUJWVkdUOHhBVTVvM1ItLVBNR1ZMUjl1Nm1IUktSQmpqbmx2OEZuaTYteWt5VUlZbDlLRGhlbk1uN1NPekdWUll6WD…
$PACB stock is up 10% today. Here's what we see in our data. - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxNRWVINlJOSmRybEdFdVBhbzBELUdTaGpGTmdTWmgzZ1AtczdMZURiYXJYYzd5ZmRaZzBjOS13V3Uxc3RzMnM0Q09zaHdHN3hmZm14Y3V1TER2c2owUGl0d2VRUVZpYVJiUGtiRHJOb25HQzltaHhtbGNVT2g5Vmo3MEM5R05SaHlTWTRNTm…
PacBio (PACB) Stock Faces Mixed Analyst Target Changes After Valuation Revisions - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMimgFBVV95cUxOZHRHanFiMDh4OXdoTjY5WHdXYy1jNWJnelp3OFpBV3ZJaG9YT1ZocTF1SlR5cnpDWHRwMnRpaUdsZmR4UU1TR1JJS0k5R245b25sZG5zMUpMWTlKWVFrdjFmMHZBMURZQ2VMNVV0WXhUSmhkN0RTUWU3Q0hlSWJQZGVqYnk3STl0d0d3eH…
[8-K] PACIFIC BIOSCIENCES OF CALIFORNIA, INC. Reports Material Event - Stock Titan
<a href="https://news.google.com/rss/articles/CBMixAFBVV95cUxQVWphZ0VCcUQxN0xYVkRkMlU0SHB5U3F6U21OZkxFLUF5WF8wVlhFTkVjUThfNXJ0QjBwOTdId0IyM2FscmpQNVJ1WmtEV1dOMmtWaU5kcTZnZFgwQ1ZjaEhTY2c5M2FDNnZLNmFTejd4VHFDcmRQOUd6TmJMUDlyU0gwbjNZTHdjMVFWVE…
Pacific Biosciences of California (PACB) Stock Sinks As Market Gains: Here's Why - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMiqgFBVV95cUxOekcwYm5FS0tGaXJLVEk2dWUwbEpFUm01aDFTLXJUazN0RjNtOUhJeG1PdVlQTTZyTEY1V0haWkE5MDFCRnpCay1QZTN0T2xVc3hLRm5aSHhFemR6ODZ3NzJaTzNLRFR3T2o4N1dGaWVyVVRQWHJBaFR2d2lxdU5obDNiZXhONGNVT3NfZV…
Pacific Biosciences of California (PACB) Stock Drops Despite Market Gains: Important Facts to Note - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMiqgFBVV95cUxQLUgtRmNzWTEzYzJoZC10dVBSUEdReURjdElHNWlfalBKX1VON1JzNm0wWjZXam5qeW1BbVU1cUZTUWxQYjNRdXJvQ21ZQWVtNlkyNFRfbXNtUG9XcmtjWG5MY092V01HVnlCOWlsQ0kycWplRlk4YW82NFU0b20tdWJ4OTFsZ1p4ZDJjVn…
PACB — Frequently Asked Questions
What is the current share price of Pacific Biosciences of California, Inc. (PACB)?
As of 2026-07-14 21:23 PDT, Pacific Biosciences of California, Inc. (PACB) trades at $1.50 on NasdaqGS. Its 52-week range is $1.12 to $2.67.
What is the market capitalisation of PACB?
Pacific Biosciences of California, Inc. (PACB) has a market capitalisation of $465.90M on NasdaqGS.
What is the P/E ratio of PACB?
PACB trades at a trailing price-to-earnings (P/E) ratio of -3.66. The industry average P/E is 25.41. Its price-to-book (P/B) ratio is 163.75.
Is PACB a good stock to buy?
This page provides a data-driven analysis of Pacific Biosciences of California, Inc. (PACB), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.